GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotricity Inc (NAS:BTCY) » Definitions » Gross Profit

Biotricity (Biotricity) Gross Profit : $7.62 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Biotricity Gross Profit?

Biotricity's gross profit for the three months ended in Dec. 2023 was $2.17 Mil. Biotricity's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $7.62 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Biotricity's gross profit for the three months ended in Dec. 2023 was $2.17 Mil. Biotricity's Revenue for the three months ended in Dec. 2023 was $2.97 Mil. Therefore, Biotricity's Gross Margin % for the quarter that ended in Dec. 2023 was 72.92%.

Biotricity had a gross margin of 72.92% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 10 years, the highest Gross Margin % of Biotricity was 65.53%. The lowest was 15.08%. And the median was 37.61%.


Biotricity Gross Profit Historical Data

The historical data trend for Biotricity's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotricity Gross Profit Chart

Biotricity Annual Data
Trend Aug14 Aug15 Dec16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.49 1.27 4.57 5.44

Biotricity Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.40 1.54 1.92 2.00 2.17

Competitive Comparison of Biotricity's Gross Profit

For the Medical Devices subindustry, Biotricity's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotricity's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's Gross Profit distribution charts can be found below:

* The bar in red indicates where Biotricity's Gross Profit falls into.



Biotricity Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Biotricity's Gross Profit for the fiscal year that ended in Mar. 2023 is calculated as

Gross Profit (A: Mar. 2023 )=Revenue - Cost of Goods Sold
=9.639 - 4.197
=5.44

Biotricity's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=2.973 - 0.805
=2.17

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.62 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Biotricity's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=2.17 / 2.973
=72.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Biotricity  (NAS:BTCY) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Biotricity had a gross margin of 72.92% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Biotricity Gross Profit Related Terms

Thank you for viewing the detailed overview of Biotricity's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotricity (Biotricity) Business Description

Traded in Other Exchanges
Address
275 Shoreline Drive, Suite 150, Redwood City, CA, USA, 94065
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed, which is a virtual clinic platform that enables clinicians to provide outstanding patient care remotely; Bioheart, which is a personal heart monitor; and Biocare health.
Executives
Chester P White director 447 BATTERY STREET, SUITE 230, SAN FRANCISCO CA 94111
Ronald W. Mcclurg director C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa director 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Stephen Salmon director 1177 HAGEN ROAD, NAPA CA 94558
Patricia J Kennedy director 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Norman M. Betts director 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Waqaas Al-siddiq director, 10 percent owner, officer: CEO and Chairman of the Board C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
John Ayanoglou officer: Chief Financial Officer C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065